Article in Microbial genomics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
7 authors.
Imraan AlasPharmaceutical Sciences Division, University of Wisconsin-Madison, Madison, WI, USA.
Doug R BraunPharmaceutical Sciences Division, University of Wisconsin-Madison, Madison, WI, USA.
Spencer S EricksenSmall Molecule Screening Facility, UW Carbone Cancer Center, Madison, WI, USA.
Rauf SalamzadeDepartment of Medical Microbiology & Immunology, University of Wisconsin-Madison, Madison, WI, USA.
Lindsay KalanDepartment of Medical Microbiology & Immunology, University of Wisconsin-Madison, Madison, WI, USA.
Scott R RajskiPharmaceutical Sciences Division, University of Wisconsin-Madison, Madison, WI, USA.
Tim S BugniPharmaceutical Sciences Division, University of Wisconsin-Madison, Madison, WI, USA.
Funding
UW COMPREHENSIVE CANCER CENTER SUPPORTP30CA014520 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI Christian Capitini · 1985 to 2026
$142.6M
Novel antimicrobials targeting MDR pathogens from animal microbial symbiontsU19AI142720 · NIAID · UNIVERSITY OF WISCONSIN-MADISON · PI ANDES, DAVID R · 2019 to 2023
$30.1M
BIOTECHNOLOGY TRAINING PROGRAMT32GM008349 · NIGMS · UNIVERSITY OF WISCONSIN-MADISON · PI FOX, BRIAN G · 1989 to 2019
$22.5M
Metabolomics driven discovery of drug leads from symbiotic bacteriaU19AI109673 · NIAID · UNIVERSITY OF WISCONSIN-MADISON · PI ANDES, DAVID R, CURRIE, CAMERON ROBERT · 2014 to 2018
$16.2M
Chemical biology of bacterial symbiontsR01AT009874 · NCCIH · HARVARD MEDICAL SCHOOL · PI CLARDY, JON · 2017 to 2019
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.